{"page_content": "2021\nRESPONSIBILITY\nREPORTImproving the Lives of People with Serious Diseases\nGOAL 2021 PROGRESS HIGHLIGHTS\nSupport organizations that offer disease prevention,\ndiagnosis and treatment for people touched by seriousdiseases.\u2022Engaged 146 global and U.S. patient advocacy and professional societies across 28 diseases\n\u2022Supported initiatives such as Elevating Cancer Equity to close gaps in healthcare in underserved communities\n\u2022Partnered to provide critical patient support during the pandemic, including COVID-19 educational resources forpatients and providers\nSet fair, value-based prices for our medicines and breakdown barriers to patient access.\n\u2022Engaged public health agencies, government and non-governmental agencies and others in our industry tofacilitate continued access to our Ebola treatments in low- and middle-income countries (LMICs)\n\u2022Granted 1,067 requests for compassionate use, based on our established criteria, to provide eligible patientsaccess to REGEN-COV (casirivimab with imdevimab), our novel antibody cocktail for COVID -19\n\u2022Delivered 2.8 million doses of REGEN-COV to the U.S. government; the government provided the treatment toeligible patients in the U.S. free of charge\u00b9\n\u2022With our partner Roche, REGEN-COV (known as Ronapreve\u2122 outside the U.S.) has been made available to patientsin more than 50 countries across many geographies and economics, including LMICs\n\u2022Provided support to 724,000 eligible patients,\u00b2 including providing free medicine through our patient supportprograms to nearly 44,000 eligible patients, a value of nearly $859 million\u00b3\nALIGNED SDG s\n\u00b9Healthcare facilities may charge fees related to administration.\n\u00b2 Regeneron patient support programs are limited to patients in U.S. states and territories.\n\u00b3 Based on 2021 year-end wholesale acquisition cost.\nINTRODUCTION IMPROVING LIVES16\nINTEGRITY & EXCELLENCE SUSTAINABLE COMMUNITIES DATA SUMMARY\uf015", "metadata": {"source": "NASDAQ_REGN_2021.pdf", "page": 15, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}